BridgeBio Pharma, Inc. - Laporan Laba Rugi (TTM)

BridgeBio Pharma, Inc.
DE ˙ MUN ˙ US10806X1028
€ 43.69 ↓ -0.45 (-1.02%)
2025-09-05
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi BridgeBio Pharma, Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 22 8 9 63 57 70 71 91 89 78 78 6 9 9 219 219 218 222 127 236
Change (%) -62.41 5.60 620.18 -9.22 22.41 1.77 27.80 -2.21 -12.42 0.17 -92.70 66.13 -1.33 2,249.75 0.24 -0.62 1.90 -42.58 85.07
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 0 0 2 3 4 5 4 3 3 3 2 2 2 2 2 4 6 9
Change (%) 1,333.94 99.23 43.29 13.25 -14.15 -20.84 -20.30 -3.69 -5.35 -1.96 -2.17 -0.04 0.00 62.12 52.63 51.61
% of Revenue 0.00 0.17 2.74 4.47 6.29 5.57 4.89 4.42 3.52 46.45 26.46 26.29 1.09 1.09 1.10 1.75 4.65 3.81
Gross Operating Profit 22 8 9 63 55 67 66 86 84 74 75 3 7 7 216 217 215 218 121 227
Change (%) -62.41 5.60 618.93 -11.56 20.24 -0.17 28.77 -1.51 -11.99 1.12 -95.95 128.13 -1.10 3,053.04 0.24 -0.63 1.23 -44.27 86.70
% of Revenue 100.00 100.00 100.00 99.83 97.26 95.53 93.71 94.43 95.11 95.58 96.48 53.55 73.54 73.71 98.91 98.91 98.90 98.25 95.35 96.19
SG&A 143 146 154 162 172 189 191 181 166 143 131 130 135 151 185 209 225 272 313 383
Change (%) 1.72 5.38 5.21 6.23 10.09 0.85 -5.01 -8.23 -13.78 -8.80 -0.23 3.52 11.66 23.04 12.63 7.93 20.96 14.89 22.25
% of Revenue 652.60 1,766.08 1,762.47 257.48 301.30 270.97 268.53 199.59 187.31 184.41 167.89 2,295.68 1,430.52 1,618.73 84.76 95.24 103.43 122.77 245.65 162.26
R&D 304 337 391 407 419 451 436 443 431 399 385 384 416 456 504 511 506 506 477 473
Change (%) 10.74 16.12 3.93 3.01 7.64 -3.31 1.48 -2.66 -7.27 -3.70 -0.24 8.50 9.44 10.56 1.43 -0.92 0.02 -5.83 -0.73
% of Revenue 1,386.85 4,085.91 4,492.95 648.35 735.70 646.94 614.70 488.09 485.83 514.45 494.57 6,762.33 4,416.49 4,898.54 230.48 233.21 232.52 228.24 374.30 200.78
OpEx 448 483 545 568 592 643 631 629 601 546 518 517 554 609 692 722 734 783 796 865
Change (%) 7.85 12.88 4.31 4.18 8.59 -1.86 -0.40 -4.36 -9.16 -5.14 -0.25 7.18 9.93 13.59 4.43 1.64 6.65 1.67 8.70
% of Revenue 2,039.45 5,851.99 6,255.42 906.00 1,039.75 922.38 889.51 693.26 678.04 703.28 665.97 9,104.46 5,873.47 6,543.56 316.34 329.54 337.04 352.75 624.60 366.84
Operating Income -426 -474 -536 -506 -535 -573 -560 -538 -513 -468 -440 -511 -544 -599 -473 -503 -516 -561 -668 -629
Change (%) 11.48 13.01 -5.70 5.85 7.12 -2.30 -3.97 -4.72 -8.60 -6.02 16.08 6.52 10.13 -21.11 6.36 2.63 8.65 19.17 -5.86
% of Revenue -1,939.45 -5,751.99 -6,155.42 -806.00 -939.75 -822.38 -789.51 -593.26 -578.04 -603.28 -565.97 -9,004.46 -5,773.47 -6,443.56 -216.34 -229.54 -237.04 -252.75 -524.60 -266.84
Interest Expense -29 -37 -42 -42 -43 -47 -57 -67 -76 -80 -80 -81 -81 -81 -85 -87 -90 -99 -118 -133
Change (%) 27.57 15.63 0.20 0.32 9.79 22.67 16.45 13.11 6.42 -0.28 0.39 0.60 0.34 4.12 2.77 3.17 10.65 18.80 12.46
% of Revenue -130.93 -444.36 -486.55 -67.69 -74.81 -67.10 -80.88 -73.70 -85.25 -103.59 -103.13 -1,419.03 -859.26 -873.79 -38.72 -39.70 -41.21 -44.74 -92.58 -56.26
Net Income -402 -449 -520 -495 -535 -563 -596 -509 -491 -481 -425 -573 -613 -643 -538 -454 -439 -536 -668 -776
Change (%) 11.57 15.87 -4.75 8.09 5.08 5.92 -14.52 -3.65 -1.95 -11.69 34.84 6.92 4.99 -16.32 -15.69 -3.30 22.08 24.68 16.24
% of Revenue -1,832.68 -5,439.74 -5,968.92 -789.46 -939.99 -806.90 -839.85 -561.78 -553.52 -619.70 -546.34 -10,096.65 -6,498.14 -6,913.92 -246.23 -207.11 -201.53 -241.44 -524.25 -329.25

Source: Capital IQ

Other Listings
US:BBIO US$ 53.38
IT:1BBIO € 44.78
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista